Skip to main content

Advertisement

SpringerLink
Log in

The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Combination therapy with docetaxel, cisplatin, and 5-FU has been shown to increase time to progression (TTP) and overall survival (OS) for patients with advanced gastric cancer; this regimen is limited by significant toxicity, including complicated neutropenia. This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen. Patients with measurable advanced and metastatic gastric or gastroesophageal cancer, aged >18 years, and with ECOG two or less, received oxaliplatin 85 mg/m2, docetaxel 50 mg/m2 on day 1, leucovorin 200 mg/m2 on days 1 and 2, and 5-FU 1,200 mg/m2 24-h infusion on days 1 and 2 of every 2-week cycle. Toxic effects were graded according to NCI-CTC version 3. Responses were classified according to World Health Organization criteria. Fifty patients were included, 47 assessed for efficacy and toxicity. Median age was 55 years. The majority had metastatic disease (72 %). The over all response was observed in 55.3 % patients. Median TTP and OS were 6 and 10 months, respectively. Grade 3 or 4 hematological toxic effects were included neutropenia, leukopenia, and thrombocytopenia observed in 21 (44.7 %), 12 (25.5 %), and 1 (2.1 %) patients, respectively. Non-hematological were diarrhea (14.9 %), fatigue (12.7 %), and peripheral neuropathy (8.5 %). Complicated neutropenia (febrile neutropenia associated with infection) was observed in one (2.1 %) patient only. Biweekly FLOT regimen has tolerable toxicity, and efficacy in line with that of DCF protocol. The FLOT regimen needs more evaluation to be considered as alternative to DCF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parkin D, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Cancer Registry of Repuplic of Slovenia. Cancer incidence in Slovenia 2007. Report no 78. Available at: http://www.onko-i.si/fileadmin/onko/dateke/dokumenti/LP-2007.pdf. Accessed 22 June 2010.

  3. Ajani J. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10:49–58.

    Article  PubMed  CAS  Google Scholar 

  4. Foukakis T, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 2007;46:277–85.

    Article  PubMed  CAS  Google Scholar 

  5. Van Custom E, Moiseyenko V, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2008;24:4991–7.

    Google Scholar 

  6. Ajani J, Moiseyenko V, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V325 study group. J Clin Oncol. 2007;25:3210–6.

    Article  PubMed  CAS  Google Scholar 

  7. Ajani J, Moiseyenko V, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V325 study group. J Clin Oncol. 2007;25:3205–9.

    Article  PubMed  CAS  Google Scholar 

  8. Khokhar NZ, Jiang Y, Benson AB, et al. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2010;4(3):96–105.

    Google Scholar 

  9. Cunningham D, Starting N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

    Article  PubMed  CAS  Google Scholar 

  10. Al Batron S, Hartman J, Probst S, et al. Phase III in metastatic gastro-esophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft internistische Onkologie. J Clin Oncol. 2008;26:1435–42.

    Article  Google Scholar 

  11. Hejna M, Raderer M, Zacherl J, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS. 1.2.001. Anticancer Drugs. 2008;19:535–9.

    PubMed  CAS  Google Scholar 

  12. Kim JG, Sohn SK, Chae YS, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer. 2008;98:542–6.

    Article  PubMed  CAS  Google Scholar 

  13. Park Y, Kim K, Choi M, et al. A phase I/II trial of docetaxel (D) and oxaliplatin (O) in patients with advanced gastric cancer (AGC). In: 2008 ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol. 2008 (abstr 15615); 26, 15S (May 20 suppl).

  14. Richards D, McCollum D, Wilfong L, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 2008;19:104–8.

    Article  PubMed  CAS  Google Scholar 

  15. Al Batron S, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658–63.

    Article  Google Scholar 

  16. Al Batron S, Kerter A, Atmaca A, et al. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Oncologie. 2007;30:29–34.

    Article  Google Scholar 

  17. Al Batron S, Hartman J, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft internistische Onkologie. Ann Oncol. 2006;19:1882–7.

    Article  Google Scholar 

  18. Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  PubMed  CAS  Google Scholar 

  19. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov), Publish Date: 9 Aug 2006.

  20. Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  PubMed  CAS  Google Scholar 

  21. Felici A, Carlini P, Ruggeri E, et al. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and fluorouracil continuous infusion plus g-csf in advanced gastric cancer : a multicentric phase II study. Cancer Chemother Pharmacol. 2006;57:59–64.

    Article  PubMed  CAS  Google Scholar 

  22. Wagner A, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.

    Article  PubMed  CAS  Google Scholar 

  23. Ohtsu A. Current status and future prospect of chemotherapy for advanced gastric cancer: a review. Gastric Cancer. 2005;8:95–102.

    Article  PubMed  CAS  Google Scholar 

  24. Ajani J, Fodor M, Tjulandin S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7.

    Article  PubMed  CAS  Google Scholar 

  25. Arnaud D, Nicola F, Roger S, et al. Docetaxel, cisplatin, and fluorouracil; Docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;1(25):3217–23.

    Google Scholar 

  26. Louvet C, Andre T, Tigaud J, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543–8.

    Article  PubMed  CAS  Google Scholar 

  27. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92:1644–9.

    Article  PubMed  Google Scholar 

  28. Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer. 2005;93:190–4.

    Article  PubMed  CAS  Google Scholar 

  29. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301–8.

    Google Scholar 

  30. Shankaran V, Mulcahy M, Hochster H, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unrespectable gastric or gastroesophageal junction (GEJ) adenocarcinoma: preliminary results of phase II study. In: ASCO gastrointestinal cancers symposium, San Francisco, CA, USA, January 2009; 15–17 (abstr 47a).

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Abeer Hussien Anter & Rasha Mohamed Abdel-Latif

  2. Mansoura, Egypt

    Abeer Hussien Anter

Authors
  1. Abeer Hussien Anter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rasha Mohamed Abdel-Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abeer Hussien Anter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anter, A.H., Abdel-Latif, R.M. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med Oncol 30, 451 (2013). https://doi.org/10.1007/s12032-012-0451-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-012-0451-1

Keywords

Search

Navigation